Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Penile Neoplasms × dacomitinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 12 Neoplasm Metastasis 4 Lung Neoplasms 4 Carcinoma, Squamous Cell 4 Squamous Cell Carcinoma of Head and Neck 2 Recurrence 2 Neoplasms 2 Head and Neck Neoplasms 2 Glioblastoma 2 Carcinoma 2 Triple Negative Breast Neoplasms 1 Penile Neoplasms 1 Mouth Neoplasms 1 Colorectal Neoplasms 1 Brain Neoplasms 1 Advanced Malignant Solid Tumors 1 Advanced Gastric Cancer 1

Interventions

Cisplatin 3 pembrolizumab 2 fludarabine phosphate 2 fludarabine 2 aldesleukin 2 aflibercept 2 Ifosfamide 2 Cyclophosphamide 2 vinflunine 1 ripretinib 1 oncogene protein E7, Human papillomavirus type 16 1 nimotuzumab 1 entinostat 1 dacomitinib 1 cabazitaxel 1 Vorinostat 1 Radiotherapy 1 Psychiatric Rehabilitation 1 Paclitaxel 1 Nivolumab 1 Neoadjuvant Therapy 1 Isotretinoin 1 Irinotecan 1 Interleukin-2 1 Interferon-alpha 1 Immunohistochemistry 1 Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1 Ganciclovir 1 Fentanyl 1 Early Intervention, Educational 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01728233 2021-05-14

HER-Uro01

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Completed

Carcinoma, Squamous Cell, Penile Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡